Rapamune (sirolimus) April 2002
Audience: Transplantation Surgeons and other healthcare professionals
FDA notified healthcare professionals of a "Dear Health Care Provider" letter issued April 24, 2002 by Wyeth, sent to members of the American Society of Transplantation and The American Society of Transplant Surgeons. The letter informs clinicians of the risk of hepatic artery thrombosis, graft loss, and death associated with the use of Rapamune (sirolimus) in de novo liver transplantation.
[April 25, 2002 - Letter - Wyeth]